Related Experiment Video

Updated: Apr 15, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.1K

Genetic Variant in the CYP19A1 Gene Associated with Coronary Artery Disease

Konstantina Bampali1, Charalampos Grassos2, Angeliki Mouzarou2

  • 1Department of Genetics and Biotechnology, Faculty of Biology, University of Athens, 15784 Athens, Greece.

Genetics Research International
|April 11, 2015
PubMed

Insights

The CYP19A1 gene's rs10046 polymorphism is linked to coronary artery disease (CAD). Individuals with the C allele have a higher likelihood of developing CAD, suggesting a genetic predisposition.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • The CYP19A1 gene encodes aromatase, crucial for estrogen biosynthesis.
  • Previous research linked CYP19A1 rs10046 polymorphism to hypertension.
  • No studies have explored the association between CYP19A1 rs10046 and coronary artery disease (CAD).

Purpose of the Study:

  • To investigate the correlation between the CYP19A1 rs10046 (C/T) polymorphism and the occurrence of coronary artery disease (CAD).
  • To determine if specific genotypes or alleles of rs10046 are associated with an increased risk of developing CAD.

Main Methods:

  • Genotyping of the CYP19A1 rs10046 polymorphism in 189 subjects.
  • Categorization of subjects into a CAD patient group (123 individuals) and a healthy control group (66 individuals) based on coronary angiography.
  • Statistical analysis of genotype and allele frequencies between the patient and control groups.

Main Results:

  • Significant differences in genotype frequencies (CC, CT, TT) of rs10046 were observed between CAD patients and controls (P = 0.034).
  • The frequency of the C allele was significantly higher in the CAD group (0.58) compared to the control group (0.44) (P = 0.010).
  • Patients carrying the C allele demonstrated a 1.771-fold increased odds of having CAD (OR = 1.771).

Conclusions:

  • The rs10046 (C/T) polymorphism in the CYP19A1 gene is significantly associated with coronary artery disease (CAD).
  • The presence of the C allele confers an increased probability of developing CAD.
  • Further research is warranted, particularly in larger female cohorts, to confirm these findings.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
228
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
114
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
154